




The relative strengths and weaknesses of Cubist Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cubist Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Cubist Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 276%, being 56% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	1,157,050
Cost of Goods Sold	230,057
Intangible Assets	266,960
Liabilities, Current	258,518
Liabilities, Non-Current	27,921
Other Assets	341,910
Other Compr. Net Income	126
Other Expenses	55,200
Other Liabilities	655,198
Other Net Income	-37,510
Other Revenues	926,359
Property and Equipment	166,465
Research and Development	277,729
Selling, General and Administrative Expense	171,788

Output Variable	Value in 1000 USD
Assets	1,932,385
Liabilities	941,637
Expenses	734,774
Revenues	926,359
Stockholders Equity	990,748
Net Income	154,075
Comprehensive Net Income	154,138
BaseVar	2,286,396
ECR before LimitedLiability	161%
Economic Capital Ratio	276%